Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

La psilocybine modifie-t-elle la densité synaptique dans les troubles cognitifs amnésiques légers

30 septembre 2026 mis à jour par: Philip Gerretsen, Centre for Addiction and Mental Health

La psilocybine modifie-t-elle la densité synaptique dans le cerveau des patients souffrant de troubles cognitifs amnésiques légers

The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brain will be higher following the ingestion of psilocybin in comparison to placebo, and that increases in SVD will be associated with improvements in cognition.

10 participants (6 with aMCI, and 4 sex and age matched healthy volunteers) will:

  • Be randomized to receive either:

    1. Two 25 mg macrodoses of psilocybin separated by 1 week.
    2. Two placebo doses separated by 1 week.
  • Receive a baseline 18F-SynVesT-1 PET scan, clinical, and neuropsychological assessments.

  • Receive a 18F-SynVesT-1 PET scan one week after the last dose of treatment.

  • Depending on available funds, receive a third PET scan at any time within 4 weeks of the screening visit to quantify tauopathy with the [18F]T807 radiotracer.

  • Receive clinical and neuropsychological testing 1, 4, and 12 weeks after the last treatment.

Researchers will compare placebo vs. experimental groups to see if psilocybin will increase SVD, and if increases in SVD are associated with cognitive improvements.

Aperçu de l'étude

Statut

Complété

Description détaillée

The proposed study will investigate the effects of on synaptic vesicular density (SVD) levels as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, and cognition (i.e., global cognition, executive function, and memory domains) in amnestic Mild Cognitive Impairment (aMCI) and healthy participants. Participants will be randomized to receive either two 25mg doses of psilocybin separated by one week, or two placebo doses separated by one week. Brain scans, clinical, and cognitive assessments will be conducted one week before, and one week, four weeks, and 12 weeks post dosing.

Type d'étude

Interventionnel

Inscription (Réel)

10

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Ontario
      • Toronto, Ontario, Canada, M5T 1R8
        • Centre for Addiction and Mental Health

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria

The aMCI participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. Inpatients or outpatients 60 to 75 years of age (on day of randomization)
  3. Diagnosis of MCI based on DSM 5 diagnostic criteria of Minor Neurocognitive Disorder
  4. Categorization of episodic memory impairment based on scores ≥ 1.0 SD lower on any of the following measures in comparison to normative data i. Logical Memory Test, ii. California Verbal Learning Test, iii. Brief Visual Memory Test
  5. Non-smoker/Non-nicotine user
  6. Montreal Cognitive Assessment (MoCA) score = < 26 and MMSE score > = 24
  7. Capable of consenting to participate in the research study
  8. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  9. Availability of a study partner who has regular contact with the participant
  10. Ability to read and communicate in English (with corrected vision and hearing, if needed)

The Healthy Control participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. 60 to 75 years of age (on day of randomization)
  3. Does not meet SCID-5 criteria for Mild Neurocognitive Disorder, Alzheimer's disease, or other major neurocognitive disorder
  4. Non-smoker/Non-nicotine user
  5. Capable of consenting to participate in the research study
  6. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  7. Availability of a study partner who has regular contact with the participant
  8. Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this clinical trial:

  1. Unwilling or incapable to consent to the study
  2. Unstable medical or any concomitant major medical or neurological illness, including presence of a relative or absolute contraindication to psilocybin, i.e. a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment.
  3. History of head trauma resulting in loss of consciousness > 30 minutes that required medical attention.
  4. DSM-5 diagnosis, with active symptoms in the last three months, of major depression; lifetime diagnosis of bipolar disorder; intellectual disability; Alzheimer's Disease; or a psychotic disorder
  5. DSM-5 substance dependence (except caffeine) within 12 months of entering the study
  6. Anticonvulsant, antidepressant, antipsychotic, mood stabilizer, opioid, or benzodiazepine use
  7. Use of serotonergic psychedelic drugs within the past 10 years
  8. Positive urine drug screen at the screening visit
  9. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks
  10. Acute suicidal or homicidal ideation
  11. Receiving treatment with medications such as levetiracetam that blocks SV2a binding, and/or inability to discontinue the following medications before study drug dosing: inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT)1A9 and (UGT)1A10, and ALDH inhibitors and alcohol dehydrogenase (ADH) inhibitors.
  12. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines
  13. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)
  14. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia)
  15. Female with childbearing potential*, pregnancy (as confirmed by a negative pregnancy test) or breastfeeding
  16. Active gender affirming hormonal treatment
  17. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I or II disorder as determined by the family medical history form and discussions with the participant.
  18. Allergies to hydroxypropyl methylcellulose *A woman/female or person who is not of childbearing potential is considered to be postmenopausal after at least 12 months without menstruation. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Females/people of childbearing potential are those who have experienced menarche and do not meet the criteria for women not of childbearing potential.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Amnestic Mild Cognitive Impairment Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

Expérimental: Healthy Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

Comparateur placebo: Amnestic Mild Cognitive Impairment Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

Comparateur placebo: Healthy Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Synaptic Vesicular Density
Délai: 3 years

Synaptic vesicular density will be assessed with PET imaging by measuring the volume of distribution (i.e., defined as the ratio of the radioligand concentration in tissue target region (CT, kBq·cm-3) to that in plasma (CP, kBq·mL-1) at equilibrium) of the [18F]SynVesT-1 radioligand in the cortical and subcortical gray matter regions in the whole brain and more specifically, the hippocampus and dorsolateral prefrontal cortex.

3 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Global Cognition
Délai: 3 years

The results of the neuropsychological battery will be combined to a global cognition composite score as a Z-score, the change of which will be a secondary outcome measure. Z-scores will be comprised of the Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure, and will be calculated based on the performance of the equated comparison group. Each domain will contribute equally to the global cognition composite score.

3 years
Memory
Délai: 3 years

A memory composite Z-score will be generated using the performance on the following individual tests: Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years
Executive Function
Délai: 3 years

An executive function composite Z-score will be generated using the performance on the following individual tests: Trail Making Test Part B, Wisconsin Card Sorting Test, Stroop Neuropsychological Screening, and the Executive Interview. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Exploratory Cognitive Outcomes
Délai: 3 years

If individual cognitive test scores are significantly different between groups, the mean difference of the individual test scores (i.e., Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure) will be analyzed separately as exploratory outcomes.

3 years
Exploratory Primary and Secondary Outcomes
Délai: 3 years

Primary and secondary outcomes will be compared between aMCI and healthy control groups.

The means of the primary outcome (i.e., volume of distribution) and secondary outcomes (i.e., cognitive composite Z-scores: global cognition, memory, and executive function) will be compared between aMCI and healthy control groups.

3 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Philip Gerretsen, MD, PhD, Centre for Addiction and Mental Health

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 novembre 2023

Achèvement primaire (Réel)

19 février 2026

Achèvement de l'étude (Réel)

19 février 2026

Dates d'inscription aux études

Première soumission

1 août 2023

Première soumission répondant aux critères de contrôle qualité

14 septembre 2023

Première publication (Réel)

18 septembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner